Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + FT825 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
FT825 | FT-825|FT 825|ONO-8250|ONO 8250|ONO8250 | HER2 (ERBB2) Immune Cell Therapy 6 | FT825 is a chimeric antigen receptor (CAR) T cell therapy targeting ERBB2 (HER2), which potentially decreases growth of ERBB2 (HER2)-expressing tumors (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06241456 | Phase I | Cetuximab + FT825 Bendamustine + Cisplatin + Docetaxel FT825 Cyclophosphamide + Fludarabine | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Recruiting | USA | 0 |